109 related articles for article (PubMed ID: 8115989)
1. Antithrombotic effects of synthetic pentasaccharide with high affinity for plasma antithrombin III in non-human primates.
Cadroy Y; Hanson SR; Harker LA
Thromb Haemost; 1993 Oct; 70(4):631-5. PubMed ID: 8115989
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin.
Cadroy Y; Harker LA; Hanson SR
J Lab Clin Med; 1989 Oct; 114(4):349-57. PubMed ID: 2551985
[TBL] [Abstract][Full Text] [Related]
3. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo.
Cadroy Y; Horbett TA; Hanson SR
J Lab Clin Med; 1989 Apr; 113(4):436-48. PubMed ID: 2522978
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates.
Yokoyama T; Kelly AB; Marzec UM; Hanson SR; Kunitada S; Harker LA
Circulation; 1995 Aug; 92(3):485-91. PubMed ID: 7634464
[TBL] [Abstract][Full Text] [Related]
5. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
6. Antifactor Xa activity and antithrombotic activity in rats of structural analogues of the minimum antithrombin III binding sequence: discovery of compounds with a longer duration of action than of the natural pentasaccharide.
Meuleman DG; Hobbelen PM; Van Dinther TG; Vogel GM; Van Boeckel CA; Moelker HC
Semin Thromb Hemost; 1991; 17 Suppl 1():112-7. PubMed ID: 2068564
[TBL] [Abstract][Full Text] [Related]
7. Dermatan sulfate inhibition of fibrin-rich thrombus formation in nonhuman primates.
Cadroy Y; Hanson SR; Harker LA
Arterioscler Thromb; 1993 Aug; 13(8):1213-7. PubMed ID: 8343496
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats.
Hobbelen PM; van Dinther TG; Vogel GM; van Boeckel CA; Moelker HC; Meuleman DG
Thromb Haemost; 1990 Apr; 63(2):265-70. PubMed ID: 2363127
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates.
Gruber A; Harker LA; Hanson SR; Kelly AB; Griffin JH
Circulation; 1991 Dec; 84(6):2454-62. PubMed ID: 1835678
[TBL] [Abstract][Full Text] [Related]
10. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
[TBL] [Abstract][Full Text] [Related]
11. Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons.
Kotzé HF; Lamprecht S; Badenhorst PN; Roodt JP; van Wyk V
Thromb Haemost; 1997 Jun; 77(6):1137-42. PubMed ID: 9241746
[TBL] [Abstract][Full Text] [Related]
12. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model.
Cadroy Y; Houghten RA; Hanson SR
J Clin Invest; 1989 Sep; 84(3):939-44. PubMed ID: 2760221
[TBL] [Abstract][Full Text] [Related]
13. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis.
Bossavy JP; Sakariassen KS; Barret A; Boneu B; Cadroy Y
Thromb Haemost; 1998 Jan; 79(1):162-8. PubMed ID: 9459343
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
Perzborn E; Strassburger J; Wilmen A; Pohlmann J; Roehrig S; Schlemmer KH; Straub A
J Thromb Haemost; 2005 Mar; 3(3):514-21. PubMed ID: 15748242
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).
Petitou M; Duchaussoy P; Jaurand G; Gourvenec F; Lederman I; Strassel JM; Bârzu T; Crépon B; Hérault JP; Lormeau JC; Bernat A; Herbert JM
J Med Chem; 1997 May; 40(11):1600-7. PubMed ID: 9171870
[TBL] [Abstract][Full Text] [Related]
16. Effect of factor Xa inhibitors on the platelet-derived microparticles procoagulant activity in vitro and in vivo in rats.
Hérault JP; Perrin B; Jongbloet C; Pflieger AM; Bernat A; Herbert JM
Thromb Haemost; 2000 Oct; 84(4):668-74. PubMed ID: 11057868
[TBL] [Abstract][Full Text] [Related]
17. Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates.
Tanaka KA; Fernández JA; Marzec UM; Kelly AB; Mohri M; Griffin JH; Hanson SR; Gruber A
Br J Haematol; 2006 Jan; 132(2):197-203. PubMed ID: 16398653
[TBL] [Abstract][Full Text] [Related]
18. Biologic studies on chemically synthesized pentasaccharide and tetrasaccharide fragments.
Choay J
Semin Thromb Hemost; 1985 Apr; 11(2):81-5. PubMed ID: 4035368
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates.
Hanson SR; Griffin JH; Harker LA; Kelly AB; Esmon CT; Gruber A
J Clin Invest; 1993 Oct; 92(4):2003-12. PubMed ID: 8408654
[TBL] [Abstract][Full Text] [Related]
20. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons.
Kelly AB; Marzec UM; Krupski W; Bass A; Cadroy Y; Hanson SR; Harker LA
Blood; 1991 Mar; 77(5):1006-12. PubMed ID: 1995089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
